NeuroMab™ Anti-Amyloid Beta 1-42 BBB Shuttle Antibody(NRZP-1022-ZP3667)

Figure 1 Binding activity of antibodies generated by transient expression of C2-modified CDRL2 constructs together with C2 chimeric heavy chain compared to chimeric antibody C2ChVHAF/ChVK generated by transient transfection and purified antibodies;

Figure 2 The results of the immunohistochemical binding experiment of chimeric antibody AF and humanized antibody H4K1;

Figure 3 Binding affinity of humanized C2 in ELISA;

Figure 4 Conformation-specific binding of mC2 to different classes of amyloid proteins. The pellet preparation in the legend of this Figure refers to Aβ1-42 fibers, and the supernatant preparation refers to amyloid monomers;

Figure 5 Aggregation analysis experiment results;

Figure 6 Decomposition and analysis of experimental results;

Figure 7 Neuroprotective experiment results of humanized antibody C2;

Figure 8 The binding of mACI-01-Ab7 C2 monoclonal antibody to amyloid fibers under transmission electron microscope;

Figure 9 Binding of mACI-01-Ab7 C2 monoclonal antibody to amyloid in Western and dot blots.